Compare Biogen Inc (BIIB) vs Western Digital Corp (WDC) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Western Digital (WDC) trades at $555.55, down 4.64% amid a sector-wide memory stock sell-off. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a net income margin of 55.07%, and robust cash flow from operations of $1.69B in 2025. Technical indicators are bearish, with price near the pivot point of $551. Analyst sentiment remains overwhelmingly positive with a 72% buy rating and a $619.07 consensus price target, suggesting significant upside potential.

The outlook is supported by AI-driven storage demand and margin expansion, but near-term volatility from memory pricing cycles and competitive pressures poses risks. The stock's high valuation multiples require sustained earnings growth to justify further appreciation.